Sufjan Stevens Says He Lost Ability to Walk From Guillain-Barr é Syndrome
The indie-rock singer-songwriter said in a statement on his website that he was expected to recover from the rare neurological condition. (Source: NYT Health)
Source: NYT Health - September 20, 2023 Category: Consumer Health News Authors: Julia Jacobs Tags: Stevens, Sufjan Guillain-Barre Syndrome Pop and Rock Music Medicine and Health Source Type: news
Mum's warning as her 12-year-old son is paralysed with rare Guillain-Barré syndrome moments after being discharged from hospital: 'He could have died'
A 12-year-old Melbourne boy who was told he was 'exaggerating' his symptoms has been diagnosed with a rare condition was paralysed moments after being discharged from hospital. (Source: the Mail online | Health)
Source: the Mail online | Health - August 11, 2023 Category: Consumer Health News Source Type: news
Federal Officials Hatch a Three-Pronged Defense Against Another ‘Tripledemic’
This fall, Americans will be urged to get shots against the flu, Covid and, if they ’re older, R.S.V. (Source: NYT Health)
Source: NYT Health - July 5, 2023 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Vaccination and Immunization Deaths (Fatalities) Elderly Coronavirus (2019-nCoV) Guillain-Barre Syndrome Respiratory Syncytial Virus (RSV) Influenza Winter (Season) GSK PLC Pfizer Inc Clinical Trials Source Type: news
Three Vaccines for Fall: What You Need to Know
Here ’s who should get the flu, Covid and R.S.V. vaccines, and when. (Source: NYT Health)
Source: NYT Health - July 5, 2023 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Vaccination and Immunization Coronavirus (2019-nCoV) Guillain-Barre Syndrome Elderly Influenza Respiratory Syncytial Virus (RSV) Immune System Viruses Winter (Season) GSK PLC Moderna Inc Novavax Inc Pfizer Inc Source Type: news
FDA Approves Pfizer ’s RSV Vaccine for Adults 60 and Older
Though agency advisers had some safety concerns, the Pfizer shot is expected to be available before the winter R.S.V. season. (Source: NYT Health)
Source: NYT Health - May 31, 2023 Category: Consumer Health News Authors: Christina Jewett Tags: Drugs (Pharmaceuticals) Vaccination and Immunization Elderly Respiratory Syncytial Virus (RSV) Guillain-Barre Syndrome Winter (Season) Pfizer Inc GSK PLC Food and Drug Administration Centers for Disease Control and Prevention Viruses Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
RSV Vaccine Approved for Older Adults
The shots would be the first vaccines available against a respiratory virus that kills thousands and leads to many more hospitalizations each year. (Source: NYT Health)
Source: NYT Health - May 3, 2023 Category: Consumer Health News Authors: Christina Jewett Tags: Vaccination and Immunization Elderly Drugs (Pharmaceuticals) Guillain-Barre Syndrome Respiratory Diseases Food and Drug Administration AstraZeneca PLC Sanofi SA Source Type: news
Why It Took So Long to Finally Get an RSV Vaccine
Respiratory syncytial virus (RSV) can dangerously compromise breathing, especially for infants and the elderly. But there has been no vaccine to prevent it—until today. On May 3, the U.S. Food and Drug Administration (FDA) approved the first vaccine against RSV, from GlaxoSmithKline (GSK), to prevent respiratory disease in people ages 60 and older. The Centers for Disease Control’s vaccine committee will make formal recommendations in June about who should receive the vaccine, but GSK says it currently has enough doses to vaccinate eligible people beginning this fall.
In studies involving 25,000 people that GSK...
Source: TIME: Health - May 3, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news
Increased risk of depression after Guillain-Barr é syndrome - Levison LS, Thomsen RW, Andersen H.
INTRODUCTION/AIMS: Guillain-Barr é syndrome (GBS) is a potentially life-threatening disorder, and some patients may develop subsequent depression related to traumatic stress or permanent loss of motor function. We determined the short-term (0-2 year) and l... (Source: SafetyLit)
Source: SafetyLit - March 15, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
COVID-19 Vaccination and Guillain-Barre Syndrome COVID-19 Vaccination and Guillain-Barre Syndrome
A new study looks at the potential association between COVID-19 vaccines and Guillain-Barre syndrome. Is there a link?Brain (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 9, 2023 Category: Intensive Care Tags: Neurology & Neurosurgery Journal Article Source Type: news
FDA Panel Backs GSK ’s RSV Vaccine for Older People
GSK Plc’s vaccine for respiratory syncytial virus won the support of a key panel of U.S. regulatory advisers for use in people aged 60 and older, as the drugmaker races against Pfizer Inc. to bring to market the first vaccine for RSV.
The panel of 12 outside advisers to the Food and Drug Administration voted unanimously on Wednesday that GSK’s data show the Arexvy vaccine is effective. The same committee voted 10-2 that company data show the shot is safe. By contrast, it had voted 7-4 with one abstention to recommend Pfizer’s vaccine as both safe and effective in preventing RSV.
[time-brightcove not-tgx=&...
Source: TIME: Health - March 2, 2023 Category: Consumer Health News Authors: Lisa Pham and Tanaz Meghjani/Bloomberg Tags: Uncategorized bloomberg wire Drugs healthscienceclimate News Source Type: news
FDA Panel Recommends 2 RSV Vaccines for Older Adults
The shots, if approved by the agency, would be the first vaccines publicly available against a respiratory virus that kills thousands a year. Some advisers did cite a small but identifiable health risk. (Source: NYT Health)
Source: NYT Health - March 1, 2023 Category: Consumer Health News Authors: Christina Jewett Tags: Vaccination and Immunization Guillain-Barre Syndrome Elderly Deaths (Fatalities) Drugs (Pharmaceuticals) Respiratory Syncytial Virus (RSV) Respiratory Diseases Viruses Food and Drug Administration Pfizer Inc GlaxoSmithKline PLC Moder Source Type: news
FDA Panel Narrowly Backs Pfizer RSV Vaccine for Older Adults
WASHINGTON — Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against the respiratory illness known as RSV.
The Food and Drug Administration panel voted 7-4 on two separate questions of whether Pfizer’s data showed the vaccine was safe and effective against the respiratory virus for people 60 and older. One panelist abstained from voting. The recommendation is non-binding and the FDA will make its own decision on the vaccine in the coming months.
The positive vote came despite concerns about rare potential reacti...
Source: TIME: Health - March 1, 2023 Category: Consumer Health News Authors: Matthew Perrone/AP Tags: Uncategorized Drugs healthscienceclimate News wire Source Type: news
FDA Panel Backs Pfizer's RSV Vaccine for Older Adults
(MedPage Today) -- In two somewhat close votes, an FDA panel of outside experts recommended the agency approve Pfizer's respiratory syncytial virus (RSV) vaccine for older adults, despite concerns over the potential risk for Guillain Barré... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 28, 2023 Category: Primary Care Source Type: news
FDA advisors recommend Pfizer RSV vaccine for older adults, despite possible Guillain-Barre risks
The Food and Drug Administration's independent advisors on Tuesday recommended Pfizer's RSV vaccine for adults ages 60 and older, despite safety concerns after two people who received the shot developed a rare neurological disorder. Though a majority of the FDA committee members backed the…#pfizer #rsv #fda #nadinepeartakindele #joincnbc #healthyreturns #biopharma #millerfisher #alejandragurtman #gurtman (Source: Reuters: Health)
Source: Reuters: Health - February 28, 2023 Category: Consumer Health News Source Type: news
